You can now read 10 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe

Business

Anika Therapeutics slumps on FDA Monovisc ruling

BEDFORD — Shares of Anika Therapeutics Inc. skidded lower Wednesday after the company said the Food and Drug Administration upheld its decision against approving the company’s osteoarthritis treatment Monovisc.

The company said it will schedule a meeting with the FDA to determine its next steps.

Continue reading below

Monovisc is designed to treat pain in patients suffering from osteoarthritis of the knee. It has been on the market in Europe since 2008 and was approved in Canada in 2009.

Anika Therapeutics stock declined $2.57, or 21.5 percent, to $9.38 in midday trading. The company’s shares have traded between $8.07 and $17.70 over the last year.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week